Evidence map›Paper›PMID 37511149›Full record

ArticleInternational journal of molecular sciences2023

Identification of a Putative SARS-CoV-2 Main Protease Inhibitor through In Silico Screening of Self-Designed Molecular Library.

Nanxin Liu, Zeyu Yang, Yuying Liu, Xintao Dang, Qingqing Zhang, Jin Wang, Xueying Liu, Jie Zhang, Xiaoyan Pan

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nanxin LiuSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.ORCID 0000-0002-5335-5118
Zeyu YangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Yuying LiuSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Xintao DangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Qingqing ZhangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Jin WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Xueying LiuSchool of Pharmacy, The Fourth Military Medical University, Xi'an 710032, China.
Jie ZhangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Xiaoyan PanSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.

Funding

Fundamental Research Funds of Xi'an Jiaotong University xzy012021053, 11913222000012National Natural Science Foundation of China No.81602965, No.82173742Natural Science Basic Research Plan in Shaanxi Province of China No.2023-JC-YB-692, No. 2023-YBSF-131
6 · The paper itself

Abstract

There have been outbreaks of SARS-CoV-2 around the world for over three years, and its variants continue to evolve. This has become a major global health threat. The main protease (M

Indexed as

COVID-19AminesAmino AcidsCoronavirus 3C ProteasesGene LibraryHumansMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsSARS-CoV-23C-like proteinase, SARS-CoV-2AminesAmino AcidsCoronavirus 3C ProteasesProtease InhibitorsCOVID-19enzymatic assaySARS-CoV-2 main proteasevirtual screening

Identifiers

PMID37511149
PMCPMC10379331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.